Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Nai-Dong Xing"'
Autor:
Xiang Zhang, Nai-Dong Xing, Cheng-Jun Lai, Rui Liu, Wei Jiao, Jue Wang, Jie Song, Zhong-Hua Xu
Publikováno v:
Chinese Medical Journal, Vol 131, Iss 16, Pp 1944-1950 (2018)
Background: MicroRNAs (miRNAs) are key regulators during tumor initiation and progression. MicroRNA-375 (MiR-375) has been proven to play a tumor-suppressive role in various types of human malignancies; however, its biological role in clear cell rena
Externí odkaz:
https://doaj.org/article/02541896a01c41d683ed30d3cbe18542
Autor:
Jiaju Lu, Sentai Ding, Yejun Qin, Koji Nishizawa, Xiao-dong Yuan, Nai-Dong Xing, Shuai Liu, Osuma Ogawa, Ying Liu, Hui Zhang, Hiroyuki Nishiyama
Publikováno v:
International Journal of Urology. 18:432-438
Objective: To investigate the relationship between Eg5 expression and prognosis of patients with non-muscle invasive bladder urothelial carcinoma. Methods: Eg5 expression was examined by immunohistochemistry in non-muscle invasive urothelial carcinom
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ad4b43c2d6008ab30e9373d9d3ceb785
https://doi.org/10.1111/j.1442-2042.2011.02751.x
https://doi.org/10.1111/j.1442-2042.2011.02751.x
Autor:
Koji Nishizawa, Nobutaka Fujii, Ryoichi Saito, Shinya Oishi, Takahiro Inoue, Sentai Ding, Osamu Ogawa, Takashi Kobayashi, Jia-Jv Lv, Hiroyuki Nishiyama, Nai-Dong Xing
Publikováno v:
Asian journal of andrology. 13(2):236-241
Docetaxel-based combination chemotherapy remains the predominant treatment for castration-resistant prostate cancer. However, taxane-related drug resistance and neurotoxicity have prompted us to develop substitute treatment strategies. Eg5 (kinesin s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::53734c463373021fbff8a8052843b99d
http://hdl.handle.net/2433/156436
http://hdl.handle.net/2433/156436
Autor:
Takayuki Sumiyoshi, Ryoichi Saito, Nai-Dong Xing, Hiroyuki Nishiyama, Yoshiyuki Matsui, Takahiro Inoue, Osamu Ogawa, Koji Yoshimura, Tomomi Kamba
Publikováno v:
International journal of clinical oncology. 18(2)
To evaluate the survival benefit of gemcitabine and paclitaxel (GT) chemotherapy for patients with metastatic urothelial cancer (UC), a retrospective analysis was performed to compare the overall survival in two periods: before (group I) and after (g
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e7a514089ac1e09b1fd68ecd27982a76
https://pubmed.ncbi.nlm.nih.gov/22410820
https://pubmed.ncbi.nlm.nih.gov/22410820